Meredith Hawkins
Albert Einstein College of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
8
all conditions, ClinicalTrials.gov
NIH grants tied to them
8
NIH RePORTER
Trial papers
140
PubMed author-name match
Trials
Studies that name Meredith Hawkins as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:16 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03685773 · The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant RecipientsAlbert Einstein College of Medicine · withdrawn · Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders · principal investigator
- Ph4NCT03608163 · Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)Albert Einstein College of Medicine · terminated · Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness · principal investigator
- Ph2NCT03566511 · Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to DiazoxideMeredith Hawkins · terminated · Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders (Including Diabetes Mellitus) · principal investigator
- Ph2NCT03540758 · Regulation of Endogenous Glucose Production by Central KATP ChannelsAlbert Einstein College of Medicine · recruiting · Diabetes Mellitus, Glucose Metabolism Disorders · principal investigator
- N/ANCT02987335 · Metabolic Characteristics of Lean Diabetes in Rural and Semi-urban India and in the United StatesAlbert Einstein College of Medicine · completed · Malnutrition; Diabetes, Diabetes · principal investigator
- Ph4NCT01028846 · Central Mechanisms That Regulate Glucose Metabolism in HumansMeredith Hawkins · terminated · Type 2 Diabetes, Glucose Metabolism Disorders, Glucose, High Blood · principal investigator
- Ph2NCT00678145 · Mechanisms of Hypoglycemia Associated Autonomic FailureAlbert Einstein College of Medicine · terminated · Diabetes Mellitus, Hypoglycemia, Autonomic Failure · principal investigator
- Ph4NCT00179400 · The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in HumansAlbert Einstein College of Medicine · completed · Type 2 Diabetes Mellitus · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Restoring Central Regulation of Glucose Production in Type 2 DiabetesR01DK069861 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · fiscal years 2006 to 2025 · $677,112 awarded in 2025Grant number is on one of their registry trials
- Enrichment ProgramP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · fiscal years 2015 to 2019 · $6,141 awarded in 2019Same name and institution; not confirmed by an ID
- Mechanisms of Hypoglycemia-Associated Authonomic FailureR01DK079974 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · fiscal years 2013 to 2017 · $151,177 awarded in 2017Grant number is on one of their registry trials
- Regulation of Hepatic Glucose FluxesR56DK069861 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · fiscal years 2012 · $167,000 awarded in 2012Same name and institution; not confirmed by an ID
- Biochemical Mechanisms of In Vivo Insulin ResistanceR01DK048321 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · fiscal years 2006 to 2008 · $455,437 awarded in 2008Same name and institution; not confirmed by an ID
- DIAZOXIDEHM01RR012248 · NCRR · ALBERT EINSTEIN COLLEGE OF MEDICINE · fiscal years 1999 to 2008 · $21,271 awarded in 2008Same name and institution; not confirmed by an ID
- CORE--ANIMAL PHYSIOLOGYP01AG021654 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · fiscal years 2003 to 2007 · $240,268 awarded in 2007Same name and institution; not confirmed by an ID
- THE ROLE OF GLUCOSAMINE PATHWAY IN NUTRITIONALLY-MEDIATER25RR015407 · NCRR · ALBERT EINSTEIN COLLEGE OF MEDICINE · fiscal years 2000 · $36,476 awarded in 2000Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:16 UTC. The ranking covers the 200 most relevant of 140 PubMed records, and a shared surname and initials can bring in a namesake. All 140 on PubMed
- Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.J Clin Oncol · 20051,555 citationsRCR 35.7
- Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.Ann Oncol · 2006457 citationsRCR 10.7
- Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.J Clin Oncol · 2008435 citationsRCR 12.2
- Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).Clin Cancer Res · 2005373 citationsRCR 8.8
- Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.J Clin Oncol · 1989362 citationsRCR 9.0
- Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.J Clin Oncol · 1993266 citationsRCR 8.8
- Pilot study of resveratrol in older adults with impaired glucose tolerance.J Gerontol A Biol Sci Med Sci · 2012228 citationsRCR 7.6
- Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.J Clin Oncol · 2005221 citationsRCR 5.2
- Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.J Clin Oncol · 1998211 citationsRCR 5.2
- Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.Diabetes · 2004210 citationsRCR 4.7